Xenografts of a human pancreatic carcinoma cell line, HPC-YS, which reacted with the monoclonal antibody (MAb) A7, were used to investigate the in vivo localization of radioiodinated MAb A7 after intraperitoneal injection. MAb A7 localized to the tumor 4 days and 8 days after injection with a tissue
Increased tumor localization by monoclonal antibody A7 after F(ab')2 fragmentation in athymic nude mice bearing human pancreatic carcinomas
✍ Scribed by Dr. Eigo Otsuji; Toshiharu Yamaguchi; Nobuki Yamaoka; Tatsuya Kotani; Hiroshi Tsurumi; Kazuya Kitamura; Nozomi Yamaguchi; Toshio Takahashi
- Publisher
- John Wiley and Sons
- Year
- 1993
- Tongue
- English
- Weight
- 613 KB
- Volume
- 53
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Much recent research has been directed toward the use of monoclonal antibodies (MoAbs) for the immunodetection of solid tumors. In pancreatic cancer, conventional immunoscintigraphy using intact MoAbs remains disappointing. In this study, ^125^I‐labeled F(ab')~2~ fragments produced by pepsin digestion of MoAb A7 were injected intravenously into nude mice bearing human pancreatic cancer, HPC‐YS, xenografts that have previously been shown to react specifically with MoAb A7. The tumor tissue/blood ratio of ^125^I‐labeled F(ab')~2~ fragments of MoAb A7 increased with time and was much higher than those for normal tissues. Moreover, the tumor tissue/blood ratio of ^125^I‐labeled F(ab')~2~ fragments was greater than that of intact MoAb A7, although the F(ab')~2~ accumulation was less than that of intact MoAb A7 in the tumor. These results suggest that F(ab')~2~ fragments of MoAb A7 may be suitable carriers of radionuclides for immunodetection of human pancreatic cancer. © 1993 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
The biodistribution and pharmacokinetics of 2 monoclonal antibodies (MAbs) specific for ovarian carcinoma, O C I25 and OV-TL3, were studied in nude mice bearing intraperitoneally (i.p.) growing human ovarian carcinoma xenografts of NIH:OVCAR-3. The ovarian carcinoma xenografts grew as non-adherent c